BACKGROUND: Anderson-Fabry disease (AFD) is an X-linked disorder caused by deficient activity of enzyme alpha-galactosidase A, resulting in the accumulation of glycosphingolipids within lysosomes. Pulmonary involvement in AFD has previously been documented, but until now has been studied only in a few series of patients without any longitudinal follow-up. The aim of this study was to compare spirometric changes in AFD patients with a matched control population and to follow the subsequent progression of the disease. MATERIALS AND METHODS: Fifty individuals (27 women, 23 men, mean age 40 +/- 14 years) with AFD from 14 families underwent a static spirometric examination under standard conditions. A set of indices was compared with that of the control population. Out of this cohort, 39 individuals not receiving enzyme replacement therapy were longitudinally evaluated (median follow-up time 24 months). RESULTS: A clinically significant reduction in spirometric parameters, corresponding to mild to severe airway obstruction, was observed in 26% of women and 61% of men. During the serial follow-up, a significant (p < 0.05) age-dependent reduction of predicted %FVC and %FEV1 values was observed in male patients, while the influence of age was not seen in female patients. The %FEF(25-75) values decreased by similar degrees in men and women and in older and younger patients, indicating that progressive bronchial disease affects the small airways first. CONCLUSIONS: We have demonstrated a clinically relevant age- and sex-dependent progressive pulmonary involvement in AFD patients. The effects of enzyme replacement therapy on pulmonary involvement remain to be demonstrated.
BACKGROUND:Anderson-Fabry disease (AFD) is an X-linked disorder caused by deficient activity of enzyme alpha-galactosidase A, resulting in the accumulation of glycosphingolipids within lysosomes. Pulmonary involvement in AFD has previously been documented, but until now has been studied only in a few series of patients without any longitudinal follow-up. The aim of this study was to compare spirometric changes in AFDpatients with a matched control population and to follow the subsequent progression of the disease. MATERIALS AND METHODS: Fifty individuals (27 women, 23 men, mean age 40 +/- 14 years) with AFD from 14 families underwent a static spirometric examination under standard conditions. A set of indices was compared with that of the control population. Out of this cohort, 39 individuals not receiving enzyme replacement therapy were longitudinally evaluated (median follow-up time 24 months). RESULTS: A clinically significant reduction in spirometric parameters, corresponding to mild to severe airway obstruction, was observed in 26% of women and 61% of men. During the serial follow-up, a significant (p < 0.05) age-dependent reduction of predicted %FVC and %FEV1 values was observed in male patients, while the influence of age was not seen in female patients. The %FEF(25-75) values decreased by similar degrees in men and women and in older and younger patients, indicating that progressive bronchial disease affects the small airways first. CONCLUSIONS: We have demonstrated a clinically relevant age- and sex-dependent progressive pulmonary involvement in AFDpatients. The effects of enzyme replacement therapy on pulmonary involvement remain to be demonstrated.
Authors: C M Eng; N Guffon; W R Wilcox; D P Germain; P Lee; S Waldek; L Caplan; G E Linthorst; R J Desnick Journal: N Engl J Med Date: 2001-07-05 Impact factor: 91.245
Authors: M Elleder; V Bradová; F Smíd; M Budĕsínský; K Harzer; B Kustermann-Kuhn; J Ledvinová; V Král; V Dorazilová Journal: Virchows Arch A Pathol Anat Histopathol Date: 1990
Authors: Robert J Desnick; Roscoe Brady; John Barranger; Allan J Collins; Dominique P Germain; Martin Goldman; Gregory Grabowski; Seymour Packman; William R Wilcox Journal: Ann Intern Med Date: 2003-02-18 Impact factor: 25.391
Authors: L K Brown; A Miller; A Bhuptani; M F Sloane; M I Zimmerman; G Schilero; C M Eng; R J Desnick Journal: Am J Respir Crit Care Med Date: 1997-03 Impact factor: 21.405
Authors: N M Siafakas; P Vermeire; N B Pride; P Paoletti; J Gibson; P Howard; J C Yernault; M Decramer; T Higenbottam; D S Postma Journal: Eur Respir J Date: 1995-08 Impact factor: 16.671
Authors: Daniel P Franzen; Albina Nowak; Sarah R Haile; Dominique Mottet; Marco Bonani; Olivier Dormond; Malcolm Kohler; Pierre A Krayenbuehl; Frederic Barbey Journal: PLoS One Date: 2017-07-25 Impact factor: 3.240
Authors: Francesca Cainelli; Dias Argandykov; Dauren Kaldarbekov; Murat Mukarov; Liên Tran Thi Phuong; Dominique P Germain Journal: Front Genet Date: 2021-04-27 Impact factor: 4.599
Authors: Martina Gaggl; Renate Kain; Peter Jaksch; Dominik Haider; Gerald Mundigler; Till Voigtländer; Raute Sunder-Plassmann; Paulus Rommer; Walter Klepetko; Gere Sunder-Plassmann Journal: Case Rep Transplant Date: 2013-04-07
Authors: Daniel Franzen; Sarah R Haile; David C Kasper; Thomas P Mechtler; Andreas J Flammer; Pierre A Krayenbühl; Albina Nowak Journal: BMJ Open Respir Res Date: 2018-04-21